Press Releases

Baylor Genetics to Showcase RNA Sequencing Breakthroughs for Rare Disease Diagnosis at 2025 AGBT Precision Health Meeting

Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced its participation in the 2025 Advances in Genome Biology and Technology (AGBT) Precision Health Conference, taking place September 8–10, 2025, in San Diego, CA. The company will present important data underscoring the clinical utility of RNA sequencing in the diagnosis of rare and previously undiagnosed diseases.

eClinical Solutions Announces Integrated Data Review Plan (IDRP) Capabilities Within elluminate Platform

Company becomes the first to centralize digital data review activities within a single platform as the industry focuses on clinical trial efficiency

Global healthcare AI experts and former UK Health Minister back AI that detects healthcare-associated infections up to 72 hours earlier

Ambience Healthcare Joins Epic Toolbox, Unlocking Advanced AI Functionality Within Haiku for Epic Customers

Baylor Genetics Hosts Webinar Highlighting the Power of Whole Genome Sequencing in Complex Pediatric Cases

Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced a clinical webinar highlighting pediatric cases in which Whole Genome Sequencing (WGS) delivered diagnostic insights that traditional genetic testing methods could not achieve.

Firstsource and Guidehealth Partner to Accelerate AI-Enabled Value-Based Care Innovation for Health Plans

VieCure Expands Community Oncology Care Network with Addition of Summit Cancer Centers

VieCure adds Summit Cancer Centers to community oncology care network

Kaleo’s AUVI-Q® (epinephrine injection, USP) Selected by Axiom Space to Help Protect Crew from Allergic Emergencies

The Axiom Space Mission 4 (Ax-4) launched from NASA’s Kennedy Space Center, and for the first time, Kaléo’s AUVI-Q® (epinephrine injection, USP) was selected by Axiom Space to support crew members in the event of an allergic emergency. Axiom Space additionally cleared AUVI-Q for inclusion on its flight surgeons’ launch and landing kits used to support the crew in the weeks leading up to launch and later during landing. Read more about the Axiom Space Mission 4: Kaleo press release Kaléo was founded 20 years ago with a mission to develop drug-delivery devices that can be trusted by those who depend on them. All medications added to the Space Mission 4 medical kit undergo rigorous review by Axiom Space. Being trusted by Axiom Space to ensure the Ax-4 Mission crew had access to a trusted epinephrine delivery device is the ultimate responsibility.

Clearwater Launches New Enterprise Cyber Risk Management Solution to Help Healthcare Organizations Reduce Cyber Risk, Strengthen Compliance, and Drive Boardroom Confidence

Longhorn Vaccines and Diagnostics Partners with Promega to Combine Complementary Offerings for Enhanced Sample Collection, Transport and Analysis

Association for Molecular Pathology Announces 2025 Award Recipients

AMP announced the recipients of its 2025 Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership and Meritorious Service Awards.

First Blood Test for Endometriosis Launched by Kephera Diagnostics

Kephera Diagnostics announced the launch of EndomTest™, the first non-invasive commercially available diagnostic test for endometriosis in the United States. This test only requires a blood sample.

Clearwater Strengthens Cyber Defense in Healthcare and the Defense Industrial Base with Enhanced Threat Intelligence from Google Cloud

Leica Biosystems Launches ChromoPlex III Detection System to Streamline Chromogenic Multiplex IHC for Reproducible, Digital-Ready Staining

Plug-and-play simplicity meets the demands of modern digital pathology workflows.

Logical Biological Launches Sister Company, Logical Antigen, Delivering Customised Antigen and Protein Purification for IVD Market

Logical Biological announced the launch of a new sister company, Logical Antigen, focused on rapid and customised delivery of high-quality antigens and biologicals, for research and manufacturing of diagnostic products.

Proscia Cements Leadership in Diagnostic Pathology with 400% Growth in Daily Cases

his momentum reflects the company’s strong role as a trusted partner to major laboratories worldwide as it helps them to unlock the clinical, operational, and financial value of AI-driven pathology at scale.

Yourgene Health Launches LightBench Discover

Three-in-one system integrates large fragment analytics, DNA size selection and fluorometric quantification for long-read sequencing

VieCure Expands Precision Oncology Ecosystem Through Strategic Partnership with Guardant Health

VieCure announced a strategic partnership with Guardant Health to embed Guardant’s next-generation sequencing-based precision oncology tests into the VieCure Halo Intelligence platform.

NIH Awards $1.9M Direct to Phase II Grant to OraLiva for AI-Driven Oral Cancer Diagnostic

I wanted to share a story that may be of interest to 360Dx: our startup OraLiva has just received a $1.9 million NIH/NIDCR Direct to Phase II SBIR grant to advance our AI-driven cancer diagnostic platform for the early detection of oral potentially malignant disorders (OPMDs) using non-invasive brush biopsy samples. The platform, called Onc In-Cyt, is designed to bring scalable, low-cost cancer diagnostics into the dental office by combining point-of-care collection with CLIA lab–based AI cytology analysis. It aims to reduce the cost, delay, and subjectivity of traditional pathology workflows — addressing a major diagnostic blind spot where millions of Americans present annually with lesions that may harbor early-stage cancer. The grant will also accelerate the company’s timeline toward a regulated, widely distributed point-of-care diagnostic device for a series of epithelial cancers (e.g., bladder, cervical, anal, esophageal). The NIH funding will support clinical validation and development of a regulated point-of-care device. You can find the NIH project summary here: https://reporter.nih.gov/search/YKKJhXympkGvSd1LJ2GC0g/project-details/10921587#description I’d be happy to share our press release or set up an interview with our team. Let me know if this could be a fit.

ClearNote Health Receives First In Vitro Diagnostic Approval for its Avantect® Pancreatic Cancer Test

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that it has received UK Conformity Assessed (UKCA) marking for its Avantect® Pancreatic Cancer Test. The UKCA mark, established as part of the United Kingdom’s independent product safety regulatory framework following its departure from the European Union, signifies compliance with UK medical device regulations and paves the way for commercial availability in the UK market.